Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00316225 · OUTCOME

Pemetrexed Population Pharmacokinetics (PK): Clearance

Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen · Source last updated 2010-07-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
milliliter per minute (mL/min)
Interval / dispersion
Standard Deviation
Time frame
Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion

What was measured

Clearance (CL) can be defined as the volume of plasma which is completely cleared of drug (pemetrexed) per unit time. Total body clearance is calculated after intravenous administration of the drug (pemetrexed) and is measured by taking plasma samples at various timepoints and measuring the amount of pemetrexed in the plasma.

Analysis population: Patients who received at least one dose of study drug.

Groups in this outcome

Pemetrexed

Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pemetrexed31

Reported measurements

Source class 1
Values in milliliter per minute (mL/min) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Pemetrexed85.621.4Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        21.4
        value
        85.6
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
Clearance (CL) can be defined as the volume of plasma which is completely cleared of drug (pemetrexed) per unit time. Total body clearance is calculated after intravenous administration of the drug (pemetrexed) and is measured by taking plasma samples at various timepoints and measuring the amount of pemetrexed in the plasma.
dispersion Type
Standard Deviation
groups
  1. description
    Pemetrexed 500 mg/m2 intravenous (IV) every 21 days for 6 cycles
    id
    OG000
    title
    Pemetrexed
param Type
MEAN
population Description
Patients who received at least one dose of study drug.
reporting Status
POSTED
time Frame
Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion
title
Pemetrexed Population Pharmacokinetics (PK): Clearance
type
SECONDARY
unit Of Measure
milliliter per minute (mL/min)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice